Equities

Theranexus SA

Theranexus SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.70
  • Today's Change-0.02 / -2.78%
  • Shares traded1.53k
  • 1 Year change-44.44%
  • Beta2.0254
Data delayed at least 15 minutes, as of Jul 26 2024 16:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Theranexus SA is a France-based company engaged in the healthcare industry. The Company is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The Company's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-6.83m
  • Incorporated2013
  • Employees19.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
GeNeuro SA0.00-14.76m1.80m19.00---------0.594-0.5940.00-0.55480.00----0.00-165.51-96.43-356.72-185.61---------------------20.96---20.13--
Biophytis SA0.00-17.03m2.12m22.00---------14.37-14.370.00-1.490.00----0.00-100.31-97.52-1,481.81-487.25-----------5.462.27------29.69--14.25--
Medesis Pharma SA0.00-3.96m3.79m10.00---------0.7916-0.79160.00-0.90710.000.3139-----206.12-126.10---300.50--70.78---2,552.190.467-26.37---------44.04------
IntegraGen SA12.54m-171.40k4.24m55.00--2.07158.080.338-0.025-0.0251.900.30411.4712.064.06227,953.30-2.01-1.93-4.78-4.4166.4165.11-1.37-1.511.57--0.3587---4.7812.61-4,783.19------
Theranexus SA0.00-6.83m5.43m19.00--2.44-----1.09-1.090.000.28630.00----0.00-70.79-42.66-82.29-47.97-----------1,058.680.6212-------3.97---33.23--
Quantum Genomics SA10.06k-3.17m6.63m3.00--7.59--658.99-0.091-0.0910.00030.01250.0007--0.00163,353.33-23.14-60.77-95.19-102.24-14,205.07-3,548.91-31,520.38-3,374.13---146.530.8615---98.34--87.28------
Acticor Biotech SA0.00-18.64m7.56m28.00---------1.55-1.550.00-0.40280.00----0.00-164.53---568.29-------------19.8510.47-------17.40------
Plant Advanced Technologies PAT SA1.68m79.16k17.61m27.00219.462.0630.3810.470.07250.07251.547.730.1118-0.41231.6062,278.520.5262-3.530.6534-4.39128.03134.214.71-33.160.4183-15.320.3402--8.568.05119.67-38.00----
Data as of Jul 26 2024. Currency figures normalised to Theranexus SA's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.